Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 April 2004

Pharmacokinetics of erythrocyte-bound daunorubicin in patients with acute leukemia

Oleksii A. Skorokhod, Tat’yana Ts. Garmaeva, Victor M. Vitvitsky, Valentin G. Isaev, Elena N. Parovichnikova, Valerii G. Savchenko, Fazoil I. Ataullakhanov

Med Sci Monit 2004; 10(4): PI55-64 :: ID: 11632

Abstract

Background:The objective of the present study was in vitro and in vivo investigation of erythrocytes as vehicles for anthracycline antibiotics.Material/Methods: The kinetics of daunorubicin binding with erythrocytes was studied in blood and in washed erythrocyte suspensions from healthy donors and patients with acute leukemia. The effect of daunorubicin on erythrocyte deformability was studied using cell filtration through membranes with 3 Km-diameter cylindrical pores. Erythrocyte-bound daunorubicin (EBD), prepared by equilibrating anticoagulated autologous blood with the antibiotic, was administered (45 or 60 mg/m2 body surface) to 14 leukemic patients as part of the 7+3 or RACOP courses. The pharmacokinetics of daunorubicin and its tolerability were studied.Results: Human erythrocytes bound daunorubicin (rubomycin) in citrated whole blood or in washed saline suspension. The equilibrium erythrocyte/medium daunorubicin concentration ratios (attained in 30–60 min at 37°C) averaged 2.9I0.5 (n=13) in blood and 5.7I0.6 (n=8) in suspension (p<0.001), without any significant difference between the erythrocytes of donors and patients with acute drug-resistant leukemia or leukemic relapses. Incubation of patient blood with daunorubicin (0.5 mg/ml cells) did not affect erythrocyte deformability (filterability). After intravenous administration, the peak drug concentration and its elimination rate were lower for EBD than for free daunorubicin. The patients tolerated EBD better than its standard free form. In nine patients who received three EBD infusions, side effects were less frequent than in those treated with free daunorubicin.
Conclusions: Our results indicate that daunorubicin-loaded erythrocytes are promising for clinical application and deserve further clinical study.

Keywords: Adolescent, Antibiotics, Antineoplastic - administration & dosage, Antibiotics, Antineoplastic - pharmacokinetics, Daunorubicin - administration & dosage, Daunorubicin - pharmacokinetics, Erythrocyte Deformability - drug effects, Erythrocytes - metabolism, Leukemia - blood, Leukemia - drug therapy, Adolescent, Antibiotics, Antineoplastic - pharmacokinetics, Daunorubicin - pharmacokinetics, Erythrocyte Deformability - drug effects, Erythrocytes - metabolism, Leukemia - drug therapy

Add Comment 0 Comments

Editorial

01 April 2025 : Editorial  

Editorial: Rapid Testing for the Avian Influenza A(H5N1) Virus is Urgently Required as Infections in Poultry and Dairy Cows are on the Rise, and so is Transmission to Humans

Dinah V. Parums

DOI: 10.12659/MSM.949109

Med Sci Monit 2025; 31:e949109

0:00

In Press

Clinical Research  

Dental Students’ Opinions on Use of Artificial Intelligence: A Survey Study

Med Sci Monit In Press; DOI: 10.12659/MSM.947658  

0:00

Database Analysis  

Defining Effect Size Standards in Temporomandibular Joint and Masticatory Muscle Research

Med Sci Monit In Press; DOI: 10.12659/MSM.948365  

0:00

Clinical Research  

Evaluating Factors Influencing Periodontal Bone Loss Using Cone Beam Computed Tomography: A Retrospective S...

Med Sci Monit In Press; DOI: 10.12659/MSM.947759  

Database Analysis  

Prognostic Significance and Immune Environment Analysis Using PANoptosis Molecular Clustering in Gastric Ca...

Med Sci Monit In Press; DOI: 10.12659/MSM.947710  

Most Viewed Current Articles

17 Jan 2024 : Review article   8,225,070

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

16 May 2023 : Clinical Research   703,027

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

01 Mar 2024 : Editorial   30,424

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...

DOI :10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

28 Jan 2024 : Review article   24,191

A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and Future

DOI :10.12659/MSM.943912

Med Sci Monit 2024; 30:e943912

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750